The Innovation Of Testing Conjugated ADC Molecules

Antibody-drug conjugates (ADCs) are expanding beyond traditional oncology applications, creating new possibilities for targeted delivery of small molecules, peptides, and oligonucleotides. These increasingly complex therapies also introduce distinct testing requirements that extend beyond those of monoclonal antibodies. Dr. Brian Woodrow explains how binding, potency, purity, free drug, drug-to-antibody ratio, and other critical quality attributes shape an effective ADC testing strategy. He also examines the containment practices needed to safely manage highly potent materials and limit occupational exposure.

Learn how integrated analytical, biosafety, microbiological, and stability testing can support ADC development from starting material through drug substance release and final product characterization, including both conventional cytotoxic ADCs and emerging conjugate modalities.